drugset / Trial / NCT00680485

Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416

NCT00680485

Phase 1 Terminated 96 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability and exposure of repeat escalating oral doses, a loading dose/maintenance dose regimen of GSK580416 and when co administered with ketoconazole, a PGP/CYP3A4 inhibitor.

Timeline

Start
2007-06
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK580416 Unknown 250 mg Oral
Subject Ketoconazole Small molecule 200 mg Oral